20830-81-3|柔红霉素|Daunorubicin|MFCD00866340-范德生物科技公司

柔红霉素

NMR下载 COA and HPLC MSDS下载
names：
Daunorubicin
CAS号：
20830-81-3
MDL Number： MFCD00866340
MF(分子式)： C27H29NO10 MW(分子量)： 527.52
EINECS:244-069-7 Reaxys Number:No data available
Pubchem ID:30323 Brand:BIOFOUNT

柔红霉素(20830-81-3,Daunorubicin)属于第一代蒽环类抗肿瘤抗生素，又称正定霉素，柔毛霉素，红比霉素，红保霉素，佐柔比星，红比脘，被广泛应用于肿瘤的临床治疗Chemicalbook。其作用机制在于细胞的核酸合成过程，能直接与DNA结合，阻碍DNA合成和依赖DNA的RNA合成反应,对RNA的影响尤为明显，并可选择性作用于嘌呤核苷。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000922-50mg	50mg	99.9%	¥ 1620.00	¥ 1620.00		Backorder	- +	¥ 0.00
YZM000922-10mg	10mg	99.9%	¥ 502.00	¥ 502.00		Backorder	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	柔红霉素(20830-81-3,Daunorubicin),道诺霉素杂质,柔红比星杂质,红保霉素,红比霉素,红卫霉素,柔毛霉素
英文别名	Daunorubicin,20830-81-3,Daunomycin,Acetyladriamycin,Leukaemomycin C
CAS号	20830-81-3
SMILES	O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O
Inchi	InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
InchiKey	STQGQHZAVUOBTE-VGBVRHCVSA-N
分子式 Formula	C27H29NO10
分子量 Molecular Weight	527.52
闪点 FP	419.5±32.9 °C
熔点 Melting point	188-190℃
沸点 Boiling point	770.0±60.0 °C at 760 mmHg
Polarizability极化度	51.5±0.5 10-24cm3
密度 Density	1.6±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±2.8 mmHg at 25°C
溶解度Solubility
性状	红色结晶性或无定形粉末
储藏条件 Storage conditions	库房通风低温干燥; 轻装轻卸、与氧化剂和酸类分开存放

柔红霉素(20830-81-3,Daunorubicin)毒性测试:

生物	测试类型	路线	报告剂量（标准化剂量）	影响	来源
human	LDLo	oral	6 mg/kg (6 mg/kg)	CARDIAC: OTHER CHANGES	Toxicology of Drugs and Chemicals, Deichmann, W.B., New York, Academic Press, Inc., 1969, -(521), 1969
rat	LD50	oral	336 mg/kg (336 mg/kg)		Yakkyoku. Pharmacy., 25(573), 1974
rat	LD50	intraperitoneal	20 mg/kg (20 mg/kg)		Advances in Teratology., 3(181), 1968
rat	LD50	subcutaneous	33200 ug/kg (33.200000000000003 mg/kg)		Yakkyoku. Pharmacy., 25(573), 1974
rat	LD50	intravenous	13 mg/kg (13 mg/kg)	BLOOD: OTHER CHANGES; SKIN AND APPENDAGES (SKIN): HAIR: OTHER	National Cancer Institute Report., -(304), 1967

柔红霉素(20830-81-3,Daunorubicin)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Daunorubicin(20830-81-3) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:柔红霉素(20830-81-3,Daunorubicin),柔红霉素试剂,柔红霉素抑制剂,柔红霉素的纯度,柔红霉素的作用,柔红霉素的用途,柔红霉素的效果,柔红霉素的使用,柔红霉素的合成,柔红霉素的生产,柔红霉素的MSDS,柔红霉素COA,柔红霉素的外观

产品说明	柔红霉素(20830-81-3,Daunorubicin)是具有有效抗肿瘤活性的DNA拓扑异构酶II的抑制剂.
Introduction	Daunorubicin (20830-81-3,柔红霉素) is atopoisomerase IIinhibitor with potent antineoplastic activities.
Application1	Daunorubicin (20830-81-3,柔红霉素) inhibitesDNA and RNA synthesisin sensitive and resistant Ehrlich ascites tumor cells.
Application2
Application3

1. Adsorptive Stripping Voltammetric Determination of Low Levels of Daunorubicin
Joseph Wang,* Meng Shan Lin and Vince Villa. ANALYST, SEPTEMBER 1987, VOL. 112
The anthracycline antibiotic daunorubicin is a widely used anticancer drug, owing to its clinical efficacy against a wide range of malignancies. This drug was the first compound to show therapeutic effects in the treatment of leukaemia in man. The cytotoxic activity of daunorubicin against cancerous cells is hampered by dose-related cardiotoxic effects. Conse-quently, a highly sensitive analytical method is essential for the evaluation and administration of this drug. Various analytical methods have been employed for this purpose, including fluorescence, radioimmunoassayn and liquid chromatographic techniques. The complex redox activity of daunorubicin, and related anthracycline antibiotics, was investigated by Rao et aZ. who discussed the redox process in relation to the antineoplastic activity of these drugs. Anthracycline antibiotics contain two electroactive moieties: a reducible quinone group and an oxidisable hydroquinone centre. The reduction of the quinone group was used for polarographic measurements of the structurally similar anthracycline, Adriamycin, down to micromolar concentrations and for measuring the binding of anthracyclines to DNA. Trace amounts of daunorubicin have not yet been determined by voltammetric procedures.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia

Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies

Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia

Overview on in vitro and in vivo investigations of nanocomposite based cancer diagnosis and therapeutics
A. P. Subramanian, S. K. Jaganathan* and Eko Supriyanto. RSC Adv.,2015, 5, 72638–72652
Nanocomposite made of nano Fe₃O₄ and polylactide nanofibers loaded with daunorubicin to cause the induction of cell death of leukemia cancer cells was reported. The number of viable cells decreased when treated with the daunorubicin loaded nanocomposite. The cellular uptake was demonstrated by the inter-cellular green fluorescence emitted by the daunorubicin drug. The cell inhibition with the 9.93 *10^-7 and 1.99 * 10^-6 mol L^-1 daunorubicin concentrations in the presence of Fe₃O₄ nanoparticles or PLA nanofibers produced no significant di?erence fromthat of the cell treated with daunorubicin alone. However, for daunorubicin concentrations at 9.93 * 10^-7 and 1.99 * 10^-6 mol L^-1, the inhibition rates increased to 31% and 46% for the cell system cultured with daunorubicin and Fe₃O₄–PLA. Chen et al. developed a poly(lactic acid) (PLA) based nanocomposites for targeted drug delivery of daunorubicin to the leukemia K562 cells.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开